SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Boberg M.) srt2:(2005-2009)"

Sökning: WFRF:(Boberg M.) > (2005-2009)

  • Resultat 1-10 av 18
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Yu, X., et al. (författare)
  • Association of UCP2 - 866 G/A polymorphism with chronic inflammatory diseases
  • 2009
  • Ingår i: Genes and Immunity. - : Springer Science and Business Media LLC. - 1466-4879 .- 1476-5470. ; 10:6, s. 601-605
  • Tidskriftsartikel (refereegranskat)abstract
    • We reported earlier that two mitochondrial gene polymorphisms, UCP2 -866 G/A (rs659366) and mtDNA nt13708 G/A (rs28359178), are associated with multiple sclerosis (MS). Here we aim to investigate whether these functional polymorphisms contribute to other eight chronic inflammatory diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Wegener' granulomatosis (WG), Churg-Strauss syndrome (CSS), Crohn's disease (CD), ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and psoriasis. Compared with individual control panels, the UCP2 -866 G/A polymorphism was associated with RA and SLE, and the mtDNA nt13708 G/A polymorphism with RA. Compared with combined controls, the UCP2 -866 G/A polymorphism was associated with SLE, WG, CD and UC. When all eight disease panels and the original MS panel were combined in a meta-analysis, the UCP2 was associated with chronic inflammatory diseases in terms of either alleles (odds ratio (OR)=0.91, 95% confidence interval (95% CI): 0.86-0.96), P=0.0003) or genotypes (OR=0.88, (95% CI: 0.82-0.95), P=0.0008), with the -866A allele associated with a decreased risk to diseases. As the -866A allele increases gene expression, our findings suggest a protective role of the UCP2 protein in chronic inflammatory diseases.
  •  
2.
  • Agnelli, G, et al. (författare)
  • Safety assessment of new antithrombotic agents : Lessons from the EXTEND study on ximelagatran.
  • 2009
  • Ingår i: Thrombosis Research. - : Elsevier BV. - 0049-3848 .- 1879-2472. ; 123:3, s. 488-497
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Ximelagatran, the first oral direct thrombin inhibitor, was shown to be an effective antithrombotic agent but was associated with potential liver toxicity after prolonged administration. OBJECTIVES AND METHODS: The aim of the EXTEND study was to assess safety and efficacy of extended administration (35 days) of ximelagatran or enoxaparin for the prevention of venous thromboembolism after elective hip replacement and hip fracture surgery. A follow-up period, including assessment of liver enzymes (in particular alanine aminotransferase; ALAT), until post-operative day 180 was planned, with visits at days 56 and 180. RESULTS: Randomization and administration of study drugs were stopped following a report of serious liver injury occurring 3 weeks after completion of ximelagatran treatment. At the time of study termination, 1158 patients had been randomized and 641 had completed the 35-day treatment; with 303 ximelagatran and 265 enoxaparin patients remaining in the study through to the day 56 follow-up visit. Overall, 58 patients showed an ALAT increase to >2x upper limit of normal: 31 treated with enoxaparin, 27 with ximelagatran. Three ximelagatran patients also showed symptoms potentially related to liver toxicity. Eleven ximelagatran patients showed an ALAT increase after study treatment ended. The clinical development of ximelagatran was terminated and the drug withdrawn from the market. Evaluation of the relative efficacy of the two treatments as specified in the protocol was impossible due to the premature termination of the study. CONCLUSIONS: Prolonged administration of ximelagatran was associated with an increased risk of liver toxicity. In a substantial proportion of patients, ALAT increase occurred after treatment withdrawal. The findings seen with ximelagatran should be considered when designing studies with new antithrombotic agents.
  •  
3.
  • Ahlgren, G., et al. (författare)
  • Imbalance of fatty acids in the base of the Baltic sea food web - a mesocosm study.
  • 2005
  • Ingår i: Canadian Journal of Fisheries and Aquatic Sciences .. ; 62:, s. 2240-2253
  • Tidskriftsartikel (refereegranskat)abstract
    • A reproductive disturbance in Baltic Sea Atlantic salmon (Salmo salar), the M74 syndrome, has been reported since early 1970s and has occasionally caused up to 90% mortality for newborn fry. Previous research has revealed that the M74 syndrome may be due to reduced levels of the vitamin thiamin, the carotenoid astaxanthin, and elevated ratios of 3/ 6 fatty acids in salmon eggs. Using mesocosm experiments, we compared the quantity (µg•L–1) and quality (mg•g–1 C) of fatty acids in microalgae and copepods in the southern Baltic Sea where the M74 syndrome is common with those in a habitat in the Norwegian Sea where the syndrome has not been observed. Daily additions were made of the nutrients N and P or N, P, and Si, copepods were added after 6–7 days, and nutrient additions were stopped after 9–10 days. Flagellates dominated completely in the Baltic Sea, whereas higher phytoplankton diversity was found in the Norwegian Sea. We found elevated 3/ 6 ratios in phytoplankton and abnormally high docosahexaenoic acid/arachidonic acid ratios (22:6 3/20:4 6) in copepods in the Baltic Sea mesocosms compared with those in the Norwegian Sea. Our results suggest that imbalance in fatty acid composition may prevail in the basic food web of the Baltic Sea.On a signalé depuis le début des années 1970 une perturbation de la reproduction, le syndrome M74, chez le saumon atlantique (Salmo salar) de la Baltique qui, à l’occasion, cause une mortalité pouvant atteindre 90 % chez les alevins néonates. Les études antérieures ont montré que le syndrome M74 peut être dû à des concentrations faibles de la vitamine thiamine et du caroténoïde l’astaxanthine et à des rapports élevés des acides gras 3/ 6 dans les oeufs de saumons. Dans des expériences de mésocosmes, nous avons comparé la quantité (µg•L–1) et la qualité (mg•g–1 C) des acides gras dans les microalgues et les copépodes dans le sud de la Baltique où le syndrome M74 est répandu à celles d’un habitat de la mer de Norvège où le syndrome n’a pas été observé. Nous avons ajouté quotidiennement les nutriments N et P ou alors N, P et Si, introduit des copépodes au bout de 6–7 jours et arrêté les additions de nutriments après 9–10 jours. Dans la Baltique, les flagellés sont dominants, alors que, dans la mer de Norvège, le phytoplancton est plus diversifié. Dans les mésocosmes de la Baltique, les rapports 3/ 6 du phytoplancton sont élevés et les rapports acide docosahexanoïque/acide arachidonique (22:6 3/20:4 6) anormalement grands chez les copépodes, par comparaison aux mésocosmes de la mer de Norvège. Nos résultats laissent croire qu’il peut y avoir un déséquilibre dans la composition en acides gras dans le réseau alimentaire de base de la Baltique.
  •  
4.
  •  
5.
  •  
6.
  • Björnsson, Einar, et al. (författare)
  • The natural history of small duct primary sclerosing cholangitis
  • 2008
  • Ingår i: Gastroenterology. - : Elsevier BV. - 1528-0012 .- 0016-5085. ; 134:4, s. 975-980
  • Tidskriftsartikel (refereegranskat)abstract
    • Background & Aims: The long-term prognosis of patients with small-duct primary sclerosing cholangitis (PSC) remains incompletely characterized. We aimed at determining the natural history and long-term outcomes of a large number of patients with small-duct PSC. Methods: Data from 83 patients with well-characterized small-duct PSC from several medical institutions in Europe and the United States were combined. Each patient with small-duct PSC was randomly matched to 2 patients with large-duct PSC by age, gender, calendar year of diagnosis, and institution. Results: The median age at diagnosis in both groups was 38 years (61% males). Nineteen (22.9%) of the 83 patients with small-duct PSC progressed to large-duct PSC in a median of 7.4 (interquartile range [IQR], 5.1–14) years. One patient with small-duct PSC who progressed to large-duct PSC was diagnosed with cholangiocarcinoma but after progression to large-duct PSC; 20 patients with large-duct PSC developed cholangiocarcinoma. Patients with small-duct PSC had a significantly longer transplantation-free survival compared with large-duct PSC patients (13 years [IQR, 10–17] vs 10 years [IQR, 6–14], respectively; hazard ratio, 3.04; 95% confidence interval: 1.82–5.06; P < .0001). Two patients with small-duct PSC who underwent liver transplantation had recurrence of small-duct PSC in the graft 9 and 13 years, respectively, after transplantation. Conclusions: Small-duct PSC is a disease of progressive potential but associated with a better long-term prognosis as compared with large-duct PSC. Small-duct PSC may recur after liver transplantation. Cholangiocarcinoma does not seem to occur in patients with small-duct PSC, unless the disease has progressed to large-duct PSC.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 18

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy